Marksans Pharma Limited (BOM:524404)
250.40
0.00 (0.00%)
At close: Jun 18, 2025
Marksans Pharma Revenue
In the fiscal year ending March 31, 2025, Marksans Pharma had annual revenue of 26.23B INR with 20.46% growth. Marksans Pharma had revenue of 7.08B in the quarter ending March 31, 2025, with 26.51% growth.
Revenue
26.23B
Revenue Growth
+20.46%
P/S Ratio
4.36
Revenue / Employee
22.99M
Employees
1,141
Market Cap
114.45B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 26.23B | 4.45B | 20.46% |
Mar 31, 2024 | 21.77B | 3.25B | 17.56% |
Mar 31, 2023 | 18.52B | 3.61B | 24.23% |
Mar 31, 2022 | 14.91B | 1.15B | 8.33% |
Mar 31, 2021 | 13.76B | 2.42B | 21.32% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,729.85B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Life Insurance Corporation of India | 8,901.58B |
Marksans Pharma News
- 9 days ago - Marksans Pharma’s UK subsidiary secures approval for Oxybutynin Hydrochloride oral solution - Business Upturn
- 17 days ago - Marksans Pharma shares jump 3% after large block deal worth Rs 257 crore - Business Upturn
- 17 days ago - Marksans Pharma Block Deal: Over 1 crore shares worth Rs 257 crore change hands at Rs 249.95 per share - Business Upturn
- 4 weeks ago - Marksans Pharma’s subsidiary Relonchem gets UK MHRA approval for Metformin Hydrochloride Oral Solution - Business Upturn
- 5 weeks ago - Marksans Pharma’s UK arm gets marketing approval for Sennosides 7.5 mg tablets - Business Upturn
- 6 weeks ago - Marksans Pharma’s UK subsidiary Relonchem gets UKMHRA nod for Gabapentin oral solution - Business Upturn
- 2 months ago - Marksans Pharma’s subsidiary receives one USFDA observation after cGMP inspection at New York facility - Business Upturn
- 4 months ago - Marksans Pharma’s subsidiary Relonchem gets UK approval for Ibuprofen and Paracetamol tablets - Business Upturn